首页 > 最新文献

Case Reports in Gastroenterology最新文献

英文 中文
A Patient with Transverse Colon Cancer Complicated by Cowden Syndrome Administered FOLFOXIRI + Bevacizumab Therapy. 1例横断结肠癌合并考登综合征患者给予FOLFOXIRI +贝伐单抗治疗。
IF 0.6 Q4 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2023-01-01 DOI: 10.1159/000529001
Kazuhiro Takehara, Yoichi Ishizaki, Kunihiko Nagakari, Masakazu Ohuchi, Masaki Fukunaga, Kazuhiro Sakamoto

Cowden syndrome is characterized by several clinical features related to tumorous lesions primarily consisting of systemic hamartomas. The mutation of a tumor suppressor gene, the PTEN gene, is etiologically involved. As gastrointestinal lesions, polyps of all digestive tracts involving the esophagus to rectum develop. In patients with Cowden syndrome, the risk of colorectal cancer may increase. However, the characteristics of colorectal cancer in these patients remain to be clarified and sufficient findings regarding chemotherapy have not been obtained. A 39-year-old man was treated with a colonic stent for colitis obstructive due to circumferential transverse colon carcinoma. After decompression, elective extended laparoscopic right hemicolectomy was performed. Preoperative systemic detailed examination revealed characteristic dermal/mucosal findings, polyposis of the upper digestive tract, and a thyroid tumor. On PTEN gene sequencing, a mutation was detected at codon 130 of exon 5, leading to a diagnosis of Cowden syndrome. Postoperative adjuvant chemotherapy was performed for 6 months, but recurrent peritoneal dissemination was observed 1 month after its completion. FOLFOXIRI + bevacizumab therapy was started. Transiently, a partial response was achieved in peritoneally disseminated nodes according to the RECIST. There was no increase in the volume of cancerous ascites. However, an increase in the volume of ascites and local relapse were noted at the completion of the tenth course. The regimen was switched to FOLFIRI + panitumumab, but peritoneal dissemination exacerbated and the patient died 18 months after surgery.

考登综合征的几个临床特征与肿瘤病变相关,主要由系统性错构瘤组成。肿瘤抑制基因PTEN基因的突变与病因有关。作为胃肠道病变,所有消化道息肉累及食道至直肠。在患有考登综合征的患者中,患结直肠癌的风险可能会增加。然而,这些患者的结直肠癌特征仍有待澄清,并且尚未获得关于化疗的充分研究结果。一名39岁的男子接受了结肠支架治疗结肠炎梗阻性肠梗阻由于环周横结肠癌。减压后行择期扩大腹腔镜右半结肠切除术。术前系统详细检查显示特征性的皮肤/粘膜发现,上消化道息肉病和甲状腺肿瘤。在PTEN基因测序中,在5外显子130密码子处检测到突变,导致诊断为考登综合征。术后辅助化疗6个月,术后1个月出现腹膜播散复发。FOLFOXIRI +贝伐单抗治疗开始。根据RECIST,腹膜播散性淋巴结暂时达到部分缓解。癌性腹水的体积没有增加。然而,在第十疗程结束时,腹水量增加,局部复发。该方案转为FOLFIRI +帕尼单抗,但腹膜传播加剧,患者在手术后18个月死亡。
{"title":"A Patient with Transverse Colon Cancer Complicated by Cowden Syndrome Administered FOLFOXIRI + Bevacizumab Therapy.","authors":"Kazuhiro Takehara,&nbsp;Yoichi Ishizaki,&nbsp;Kunihiko Nagakari,&nbsp;Masakazu Ohuchi,&nbsp;Masaki Fukunaga,&nbsp;Kazuhiro Sakamoto","doi":"10.1159/000529001","DOIUrl":"https://doi.org/10.1159/000529001","url":null,"abstract":"<p><p>Cowden syndrome is characterized by several clinical features related to tumorous lesions primarily consisting of systemic hamartomas. The mutation of a tumor suppressor gene, the <i>PTEN</i> gene, is etiologically involved. As gastrointestinal lesions, polyps of all digestive tracts involving the esophagus to rectum develop. In patients with Cowden syndrome, the risk of colorectal cancer may increase. However, the characteristics of colorectal cancer in these patients remain to be clarified and sufficient findings regarding chemotherapy have not been obtained. A 39-year-old man was treated with a colonic stent for colitis obstructive due to circumferential transverse colon carcinoma. After decompression, elective extended laparoscopic right hemicolectomy was performed. Preoperative systemic detailed examination revealed characteristic dermal/mucosal findings, polyposis of the upper digestive tract, and a thyroid tumor. On <i>PTEN</i> gene sequencing, a mutation was detected at codon 130 of exon 5, leading to a diagnosis of Cowden syndrome. Postoperative adjuvant chemotherapy was performed for 6 months, but recurrent peritoneal dissemination was observed 1 month after its completion. FOLFOXIRI + bevacizumab therapy was started. Transiently, a partial response was achieved in peritoneally disseminated nodes according to the RECIST. There was no increase in the volume of cancerous ascites. However, an increase in the volume of ascites and local relapse were noted at the completion of the tenth course. The regimen was switched to FOLFIRI + panitumumab, but peritoneal dissemination exacerbated and the patient died 18 months after surgery.</p>","PeriodicalId":9614,"journal":{"name":"Case Reports in Gastroenterology","volume":"17 1","pages":"56-63"},"PeriodicalIF":0.6,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/78/e6/crg-2022-0017-0001-529001.PMC9891847.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10661684","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Progression of Recurrent Pancreatitis to Chronic Pancreatitis within 3 Years due to SPINK1 Mutation IVS3+2T>C. 3年内因SPINK1突变IVS3+2T>C导致的复发性胰腺炎进展为慢性胰腺炎
IF 0.6 Q4 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2023-01-01 DOI: 10.1159/000528768
Susumu Horitani, Masahiro Tsujimae, Arata Sakai, Atsuhiro Masuda, Kae Nagao, Shinya Kohashi, Noriko Inomata, Hisahiro Uemura, Shigeto Masuda, Masanori Gonda, Shohei Abe, Kohei Yamakawa, Shigeto Ashina, Yasutaka Yamada, Takeshi Tanaka, Ryota Nakano, Takashi Kobayashi, Hideyuki Shiomi, Yuzo Kodama

When the etiology of pancreatitis cannot be determined despite sufficient investigation, recurrence and progression to chronic pancreatitis often involve genetic mutations. Herein, we describe a case of recurrent pancreatitis with the IVS3+2T>C mutation in the serine protease inhibitor Kazal type 1 (SPINK1) gene that progressed to chronic pancreatitis in only 3 years. A 35-year-old man was referred to our hospital, where he was diagnosed with mild pancreatitis and was treated conservatively. However, the patient experienced recurrent episodes of pancreatitis, which progressed to become chronic pancreatitis with a pancreatic calcification 1 year later. After 3 years, the patient developed pancreatic duct stenosis and required a pancreatic duct stent placement. Regarding the cause of chronic pancreatitis, alcohol abuse was ruled out based on history taking. Considering the course of treatment, autoimmune pancreatitis and obstructive pancreatitis, such as pancreatic divisum, were also ruled out. Finally, a germline genetic test was performed to determine the etiology of pancreatitis, which revealed the IVS3+2T>C mutation in SPINK1. This case shows the importance of genetic testing in patients with idiopathic pancreatitis to determine their etiology and is a rare incident that can report the progression of the disease from acute to chronic pancreatitis.

当胰腺炎的病因无法确定,尽管有充分的调查,复发和进展到慢性胰腺炎往往涉及基因突变。在此,我们描述了一例复发性胰腺炎,丝氨酸蛋白酶抑制剂Kazal 1型(SPINK1)基因IVS3+2T>C突变,仅在3年内就发展为慢性胰腺炎。一名35岁男子被转介至我院,在那里他被诊断为轻度胰腺炎并接受保守治疗。然而,患者胰腺炎反复发作,1年后发展为慢性胰腺炎伴胰腺钙化。3年后,患者出现胰管狭窄,需要胰管支架置入。关于慢性胰腺炎的病因,根据病史排除了酒精滥用。考虑到治疗过程,自身免疫性胰腺炎和梗阻性胰腺炎,如胰腺分裂,也被排除。最后,通过种系基因检测确定胰腺炎的病因,发现SPINK1基因IVS3+2T>C突变。这个病例显示了基因检测在特发性胰腺炎患者中确定其病因的重要性,并且是一个罕见的事件,可以报告疾病从急性到慢性胰腺炎的进展。
{"title":"Progression of Recurrent Pancreatitis to Chronic Pancreatitis within 3 Years due to <i>SPINK1</i> Mutation IVS3+2T>C.","authors":"Susumu Horitani,&nbsp;Masahiro Tsujimae,&nbsp;Arata Sakai,&nbsp;Atsuhiro Masuda,&nbsp;Kae Nagao,&nbsp;Shinya Kohashi,&nbsp;Noriko Inomata,&nbsp;Hisahiro Uemura,&nbsp;Shigeto Masuda,&nbsp;Masanori Gonda,&nbsp;Shohei Abe,&nbsp;Kohei Yamakawa,&nbsp;Shigeto Ashina,&nbsp;Yasutaka Yamada,&nbsp;Takeshi Tanaka,&nbsp;Ryota Nakano,&nbsp;Takashi Kobayashi,&nbsp;Hideyuki Shiomi,&nbsp;Yuzo Kodama","doi":"10.1159/000528768","DOIUrl":"https://doi.org/10.1159/000528768","url":null,"abstract":"<p><p>When the etiology of pancreatitis cannot be determined despite sufficient investigation, recurrence and progression to chronic pancreatitis often involve genetic mutations. Herein, we describe a case of recurrent pancreatitis with the IVS3+2T>C mutation in the serine protease inhibitor Kazal type 1 (<i>SPINK1</i>) gene that progressed to chronic pancreatitis in only 3 years. A 35-year-old man was referred to our hospital, where he was diagnosed with mild pancreatitis and was treated conservatively. However, the patient experienced recurrent episodes of pancreatitis, which progressed to become chronic pancreatitis with a pancreatic calcification 1 year later. After 3 years, the patient developed pancreatic duct stenosis and required a pancreatic duct stent placement. Regarding the cause of chronic pancreatitis, alcohol abuse was ruled out based on history taking. Considering the course of treatment, autoimmune pancreatitis and obstructive pancreatitis, such as pancreatic divisum, were also ruled out. Finally, a germline genetic test was performed to determine the etiology of pancreatitis, which revealed the IVS3+2T>C mutation in <i>SPINK1</i>. This case shows the importance of genetic testing in patients with idiopathic pancreatitis to determine their etiology and is a rare incident that can report the progression of the disease from acute to chronic pancreatitis.</p>","PeriodicalId":9614,"journal":{"name":"Case Reports in Gastroenterology","volume":"17 1","pages":"49-55"},"PeriodicalIF":0.6,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/3d/39/crg-2022-0017-0001-528768.PMC9891844.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10661685","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Benefit of Continuation of Low-Dose Imatinib for Gastrointestinal Stromal Tumors despite Adverse Events with Regular-Dose Imatinib. 尽管常规剂量伊马替尼有不良事件,但继续使用低剂量伊马替尼治疗胃肠道间质肿瘤的益处
IF 0.6 Q4 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2023-01-01 DOI: 10.1159/000529002
Ryo Katsumata, Yasumasa Monobe, Yosuke Katata, Hideyo Fujiwara, Takashi Urano, Akihisa Akagi, Kotone Tsujimoto, Takako Konishi, Noriaki Manabe, Tomoari Kamada, Hirofumi Kawamoto, Tomoki Yamatsuji, Yoshio Naomoto

Tyrosine kinase inhibitors (TKIs) such as imatinib improve the prognosis of patients with gastrointestinal stromal tumors (GISTs). However, treatment options for GISTs are still limited, and the continuation of TKIs is difficult due to adverse events in some cases. The effectiveness of low-dose imatinib is unclear. We report 2 cases to show effectiveness of low-dose imatinib in patients with adverse events. The first case is a male in his early 60s with a history of intestinal GIST resection who was diagnosed with recurrent GIST with peritoneal dissemination. He was started on low-dose imatinib (300 mg) because of a history of subconjunctival hemorrhage after receiving postoperative imatinib. Follow-up contrast-enhanced ultrasonography revealed that the tumors had shrunk in size and number after 2 months of treatment with 300-mg imatinib. He continued this treatment and showed partial response for 8 months. The second case is a female in her late 70s with rectal GIST who was treated with imatinib 400 mg. Due to a severe skin lesion, she changed her treatment to sunitinib 2 months after initiation. However, new metastasis in the liver was confirmed after 4 months of administration of sunitinib. She underwent surgical esection of the rectal tumor to reduce the volume. After the surgery, low-dose imatinib (300 mg) with oral steroids was adopted. Follow-up confirmed the absence of recurrence at the rectum and no increase in hepatic tumor size for 18 months. Aggressive treatment with low-dose imatinib instead of discontinuation or alteration of treatment may benefit patients with unresectable and postoperative GISTs with sensible mutation to imatinib.

酪氨酸激酶抑制剂(TKIs)如伊马替尼可改善胃肠道间质瘤(gist)患者的预后。然而,gist的治疗选择仍然有限,并且由于某些病例的不良事件,tki的持续治疗很困难。低剂量伊马替尼的有效性尚不清楚。我们报告了2例低剂量伊马替尼对不良事件患者的有效性。第一个病例是60岁出头的男性,有肠间质瘤切除术史,诊断为复发性间质瘤伴腹膜播散。他开始使用低剂量伊马替尼(300mg),因为术后接受伊马替尼后有结膜下出血史。随访超声造影显示,经300-mg伊马替尼治疗2个月后,肿瘤体积和数量缩小。他继续这种治疗,并显示部分缓解了8个月。第二个病例是一位70多岁的女性直肠GIST患者,接受伊马替尼400mg治疗。由于严重的皮肤病变,她在开始治疗2个月后改为舒尼替尼。然而,服用舒尼替尼4个月后,肝脏出现新的转移。她接受手术切除直肠肿瘤以减小体积。术后给予低剂量伊马替尼(300 mg)联合口服类固醇。随访18个月,直肠无复发,肝肿瘤大小无增加。积极治疗低剂量伊马替尼而不是停止或改变治疗可能有利于不可切除和术后对伊马替尼敏感突变的胃肠道间质瘤患者。
{"title":"Benefit of Continuation of Low-Dose Imatinib for Gastrointestinal Stromal Tumors despite Adverse Events with Regular-Dose Imatinib.","authors":"Ryo Katsumata,&nbsp;Yasumasa Monobe,&nbsp;Yosuke Katata,&nbsp;Hideyo Fujiwara,&nbsp;Takashi Urano,&nbsp;Akihisa Akagi,&nbsp;Kotone Tsujimoto,&nbsp;Takako Konishi,&nbsp;Noriaki Manabe,&nbsp;Tomoari Kamada,&nbsp;Hirofumi Kawamoto,&nbsp;Tomoki Yamatsuji,&nbsp;Yoshio Naomoto","doi":"10.1159/000529002","DOIUrl":"https://doi.org/10.1159/000529002","url":null,"abstract":"<p><p>Tyrosine kinase inhibitors (TKIs) such as imatinib improve the prognosis of patients with gastrointestinal stromal tumors (GISTs). However, treatment options for GISTs are still limited, and the continuation of TKIs is difficult due to adverse events in some cases. The effectiveness of low-dose imatinib is unclear. We report 2 cases to show effectiveness of low-dose imatinib in patients with adverse events. The first case is a male in his early 60s with a history of intestinal GIST resection who was diagnosed with recurrent GIST with peritoneal dissemination. He was started on low-dose imatinib (300 mg) because of a history of subconjunctival hemorrhage after receiving postoperative imatinib. Follow-up contrast-enhanced ultrasonography revealed that the tumors had shrunk in size and number after 2 months of treatment with 300-mg imatinib. He continued this treatment and showed partial response for 8 months. The second case is a female in her late 70s with rectal GIST who was treated with imatinib 400 mg. Due to a severe skin lesion, she changed her treatment to sunitinib 2 months after initiation. However, new metastasis in the liver was confirmed after 4 months of administration of sunitinib. She underwent surgical esection of the rectal tumor to reduce the volume. After the surgery, low-dose imatinib (300 mg) with oral steroids was adopted. Follow-up confirmed the absence of recurrence at the rectum and no increase in hepatic tumor size for 18 months. Aggressive treatment with low-dose imatinib instead of discontinuation or alteration of treatment may benefit patients with unresectable and postoperative GISTs with sensible mutation to imatinib.</p>","PeriodicalId":9614,"journal":{"name":"Case Reports in Gastroenterology","volume":"17 1","pages":"109-116"},"PeriodicalIF":0.6,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/8f/71/crg-2022-0017-0001-529002.PMC9938401.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10768583","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Granular Cell Tumor of the Ascending Colon. 升结肠颗粒细胞瘤。
IF 0.6 Q4 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2023-01-01 DOI: 10.1159/000529170
Samyak Dhruv, Kuldeepsinh P Atodaria, Dhineshreddy Gurala, Talal El Imad, Jeffrey Abergel

Granular cell tumor (GCT) was first described by Abrikossoff in 1926. It is a mostly benign tumor with rare malignant transformation. It is defined as a soft tissue neoplasm with abundant eosinophilic cytoplasm. The mean age of diagnosis for GCT is around 45 years. It is rare for GCT to be found in the gastrointestinal (GI) tract. Within the subset of GI tract, the colon is an extremely rare site for it to be found. Franburg-Smith histopathology criteria are used to differentiate a benign from a malignant GCT. The malignant form is aggressive with high recurrence rates after resection. Histopathology and immunohistochemical stains are used to make a definitive diagnosis. Herein, we present a rare case of an ascending colon polyp that was resected and found to be a benign GCT.

颗粒细胞瘤(GCT)最早是由Abrikossoff于1926年描述的。多为良性肿瘤,少见恶性转化。它被定义为一种具有丰富嗜酸性细胞质的软组织肿瘤。GCT的平均诊断年龄在45岁左右。在胃肠道中发现GCT是罕见的。在胃肠道的子集中,结肠是一个极其罕见的部位。Franburg-Smith组织病理学标准用于区分良性和恶性GCT。恶性肿瘤具有侵袭性,术后复发率高。组织病理学和免疫组织化学染色用于明确诊断。在此,我们报告一例罕见的升结肠息肉,切除后发现是良性的GCT。
{"title":"Granular Cell Tumor of the Ascending Colon.","authors":"Samyak Dhruv,&nbsp;Kuldeepsinh P Atodaria,&nbsp;Dhineshreddy Gurala,&nbsp;Talal El Imad,&nbsp;Jeffrey Abergel","doi":"10.1159/000529170","DOIUrl":"https://doi.org/10.1159/000529170","url":null,"abstract":"<p><p>Granular cell tumor (GCT) was first described by Abrikossoff in 1926. It is a mostly benign tumor with rare malignant transformation. It is defined as a soft tissue neoplasm with abundant eosinophilic cytoplasm. The mean age of diagnosis for GCT is around 45 years. It is rare for GCT to be found in the gastrointestinal (GI) tract. Within the subset of GI tract, the colon is an extremely rare site for it to be found. Franburg-Smith histopathology criteria are used to differentiate a benign from a malignant GCT. The malignant form is aggressive with high recurrence rates after resection. Histopathology and immunohistochemical stains are used to make a definitive diagnosis. Herein, we present a rare case of an ascending colon polyp that was resected and found to be a benign GCT.</p>","PeriodicalId":9614,"journal":{"name":"Case Reports in Gastroenterology","volume":"17 1","pages":"104-108"},"PeriodicalIF":0.6,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/a0/b1/crg-2022-0017-0001-529170.PMC9938395.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10768586","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Hypereosinophilic Syndrome Secondary to Ulcerative Colitis and Primary Sclerosing Cholangitis. 继发于溃疡性结肠炎和原发性硬化性胆管炎的嗜酸性粒细胞增多综合征。
IF 0.6 Q4 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2023-01-01 DOI: 10.1159/000527380
Davi Viana Ramos, Diogo Delgado Dotta, Luísa Leite Barros

Hypereosinophilic syndrome (HES) is a rare condition characterized by hypereosinophilia in peripheral blood or tissue infiltrate and organ damage. HES has been associated with several diseases, including inflammatory bowel diseases (IBDs), especially ulcerative colitis (UC). In this report, we describe a case of a UC and primary sclerosing cholangitis patient who was diagnosed with HES and severe cardiovascular and neurological injury. During hospitalization, an extensive diagnostic workup was performed and secondary causes of hypereosinophilia were ruled out. The patient was treated with glucocorticoids and full anticoagulation with significant clinical improvement and a marked reduction in the eosinophil count. In the literature, hypereosinophilia in the IBD population has been related to the severity of the disease and worse prognosis. The high index of clinical suspicion and the accurate diagnosis of HES are essential to avoid delay in therapy and prevent complications.

高嗜酸性粒细胞综合征(HES)是一种以外周血或组织浸润及器官损伤为特征的罕见疾病。HES与几种疾病有关,包括炎症性肠病(IBDs),特别是溃疡性结肠炎(UC)。在本报告中,我们描述了一例UC和原发性硬化性胆管炎患者,他被诊断为HES和严重的心血管和神经损伤。住院期间,进行了广泛的诊断检查,排除了嗜酸性粒细胞增多症的继发原因。患者接受糖皮质激素和全面抗凝治疗,临床症状明显改善,嗜酸性粒细胞计数明显减少。在文献中,IBD人群中的嗜酸性细胞增多症与疾病的严重程度和较差的预后有关。高临床怀疑指数和准确诊断是避免延误治疗和预防并发症的关键。
{"title":"Hypereosinophilic Syndrome Secondary to Ulcerative Colitis and Primary Sclerosing Cholangitis.","authors":"Davi Viana Ramos,&nbsp;Diogo Delgado Dotta,&nbsp;Luísa Leite Barros","doi":"10.1159/000527380","DOIUrl":"https://doi.org/10.1159/000527380","url":null,"abstract":"<p><p>Hypereosinophilic syndrome (HES) is a rare condition characterized by hypereosinophilia in peripheral blood or tissue infiltrate and organ damage. HES has been associated with several diseases, including inflammatory bowel diseases (IBDs), especially ulcerative colitis (UC). In this report, we describe a case of a UC and primary sclerosing cholangitis patient who was diagnosed with HES and severe cardiovascular and neurological injury. During hospitalization, an extensive diagnostic workup was performed and secondary causes of hypereosinophilia were ruled out. The patient was treated with glucocorticoids and full anticoagulation with significant clinical improvement and a marked reduction in the eosinophil count. In the literature, hypereosinophilia in the IBD population has been related to the severity of the disease and worse prognosis. The high index of clinical suspicion and the accurate diagnosis of HES are essential to avoid delay in therapy and prevent complications.</p>","PeriodicalId":9614,"journal":{"name":"Case Reports in Gastroenterology","volume":"17 1","pages":"41"},"PeriodicalIF":0.6,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/11/19/crg-2022-0017-0001-527380.PMC9893995.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9288033","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Endoscopic Laryngopharyngeal Surgery Combined with Endoscopic Submucosal Dissection as a Treatment Option for Superficial Hypopharyngeal Cancer with Suspected Synchronous Lymph Node Metastasis. 内镜下咽手术联合内镜下粘膜剥离术治疗怀疑有同步淋巴结转移的浅表性下咽癌。
IF 0.6 Q4 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2023-01-01 DOI: 10.1159/000528424
Shinya Sugimoto, Tomohito Fuke, Daisuke Kobayashi, Mamika Kaneko, Taishi Temma, Tatsuma Nomura, Nobuyuki Tsuda, Mayu Kawabata, Ryutaro Matsushima, Hirohisa Hisada, Satoshi Hayashi, Toji Murabayashi, Jun Oyamada, Akira Kamei, Nobukazu Fuwa, Tadashi Yabana, Hiroyuki Yamada, Hayato Nakagawa

We report 4 cases of hypopharyngeal cancer preoperatively suspected with synchronous lymph node metastases. Pathologic lymph node metastasis was confirmed in three of the four cases. All 4 cases underwent endoscopic laryngopharyngeal surgery (ELPS) combined with endoscopic submucosal dissection (ESD) and subsequent lymph node dissection as an optional treatment rather than the standard treatment. Peroral resection for primary site was selected because of the expected decline in quality of life (QoL) after radical surgery. Among 4 patients, one developed local recurrence; however, the other three remained recurrence-free and survived without any additional treatment. Furthermore, the patient who developed local recurrence had a recurrence-free survival for more than 5 years, with additional chemoradiation therapy. No disorders in speech, swallowing, or breathing was observed during the follow-up period. ELPS combined with ESD is generally indicated for laryngopharyngeal cancer without synchronous lymph node metastasis. However, this can be a treatment option for patients may wish to preserve a greater QoL after treatment. In the future, when more data on the results and long-term prognosis of this treatment are accumulated, it may be possible to discuss its validity further.

我们报告4例术前怀疑有同步淋巴结转移的下咽癌。4例中有3例经病理证实有淋巴结转移。4例患者均行内镜下喉咽手术(ELPS)联合内镜下粘膜清扫(ESD)及后续淋巴结清扫作为可选治疗,而非标准治疗。由于预期根治性手术后生活质量(QoL)会下降,因此选择经口切除原发部位。4例患者中1例局部复发;然而,另外三名患者没有复发,没有接受任何额外治疗。此外,局部复发的患者在接受额外的放化疗后无复发生存期超过5年。随访期间未见言语、吞咽或呼吸障碍。ELPS联合ESD一般适用于无同步淋巴结转移的咽喉癌。然而,对于希望在治疗后保持更大生活质量的患者,这可能是一种治疗选择。在未来,当更多关于这种治疗的结果和长期预后的数据积累时,可能有可能进一步讨论其有效性。
{"title":"Endoscopic Laryngopharyngeal Surgery Combined with Endoscopic Submucosal Dissection as a Treatment Option for Superficial Hypopharyngeal Cancer with Suspected Synchronous Lymph Node Metastasis.","authors":"Shinya Sugimoto,&nbsp;Tomohito Fuke,&nbsp;Daisuke Kobayashi,&nbsp;Mamika Kaneko,&nbsp;Taishi Temma,&nbsp;Tatsuma Nomura,&nbsp;Nobuyuki Tsuda,&nbsp;Mayu Kawabata,&nbsp;Ryutaro Matsushima,&nbsp;Hirohisa Hisada,&nbsp;Satoshi Hayashi,&nbsp;Toji Murabayashi,&nbsp;Jun Oyamada,&nbsp;Akira Kamei,&nbsp;Nobukazu Fuwa,&nbsp;Tadashi Yabana,&nbsp;Hiroyuki Yamada,&nbsp;Hayato Nakagawa","doi":"10.1159/000528424","DOIUrl":"https://doi.org/10.1159/000528424","url":null,"abstract":"<p><p>We report 4 cases of hypopharyngeal cancer preoperatively suspected with synchronous lymph node metastases. Pathologic lymph node metastasis was confirmed in three of the four cases. All 4 cases underwent endoscopic laryngopharyngeal surgery (ELPS) combined with endoscopic submucosal dissection (ESD) and subsequent lymph node dissection as an optional treatment rather than the standard treatment. Peroral resection for primary site was selected because of the expected decline in quality of life (QoL) after radical surgery. Among 4 patients, one developed local recurrence; however, the other three remained recurrence-free and survived without any additional treatment. Furthermore, the patient who developed local recurrence had a recurrence-free survival for more than 5 years, with additional chemoradiation therapy. No disorders in speech, swallowing, or breathing was observed during the follow-up period. ELPS combined with ESD is generally indicated for laryngopharyngeal cancer without synchronous lymph node metastasis. However, this can be a treatment option for patients may wish to preserve a greater QoL after treatment. In the future, when more data on the results and long-term prognosis of this treatment are accumulated, it may be possible to discuss its validity further.</p>","PeriodicalId":9614,"journal":{"name":"Case Reports in Gastroenterology","volume":"17 1","pages":"1-13"},"PeriodicalIF":0.6,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/1a/17/crg-2022-0017-0001-528424.PMC9841794.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10550787","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Gastric Metastasis 5 Years after Primary Invasive Lobular Adenocarcinoma of the Breast. 原发性浸润性乳腺小叶腺癌后5年发生胃转移。
IF 0.6 Q4 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2023-01-01 DOI: 10.1159/000528506
Dongmin Shin, Haozhe Sun, Nikhitha Mantri, Harish Patel

Breast cancers metastasize most commonly to the bone, brain, liver, and lungs, but rarely to the gastrointestinal tract. Although metastatic breast carcinomas in the stomach can be confused with primary gastric cancers due to their nonspecific presentation and rare incidence, it is important to differentiate the two since the treatment is different. Clinical suspicion is imperative for a prompt endoscopic evaluation and a definitive diagnosis that will lead to appropriate treatment. Therefore, it is important for clinicians to be aware of the possibility of gastric metastasis of breast cancers, especially in those with a history of invasive lobular breast carcinoma and a new onset of gastrointestinal symptoms.

乳腺癌最常转移到骨、脑、肝和肺,但很少转移到胃肠道。虽然胃转移性乳腺癌由于其非特异性的表现和罕见的发病率可能与原发性胃癌相混淆,但由于治疗方法不同,区分两者是很重要的。临床怀疑是必要的及时内镜评估和明确的诊断,将导致适当的治疗。因此,临床医生应注意乳腺癌胃转移的可能性,特别是那些有浸润性小叶乳腺癌病史和新出现胃肠道症状的患者。
{"title":"Gastric Metastasis 5 Years after Primary Invasive Lobular Adenocarcinoma of the Breast.","authors":"Dongmin Shin,&nbsp;Haozhe Sun,&nbsp;Nikhitha Mantri,&nbsp;Harish Patel","doi":"10.1159/000528506","DOIUrl":"https://doi.org/10.1159/000528506","url":null,"abstract":"<p><p>Breast cancers metastasize most commonly to the bone, brain, liver, and lungs, but rarely to the gastrointestinal tract. Although metastatic breast carcinomas in the stomach can be confused with primary gastric cancers due to their nonspecific presentation and rare incidence, it is important to differentiate the two since the treatment is different. Clinical suspicion is imperative for a prompt endoscopic evaluation and a definitive diagnosis that will lead to appropriate treatment. Therefore, it is important for clinicians to be aware of the possibility of gastric metastasis of breast cancers, especially in those with a history of invasive lobular breast carcinoma and a new onset of gastrointestinal symptoms.</p>","PeriodicalId":9614,"journal":{"name":"Case Reports in Gastroenterology","volume":"17 1","pages":"221-227"},"PeriodicalIF":0.6,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10294209/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9740387","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Right Hepatic and Portal Vein Embolization before Right Hepatectomy for Colorectal Cancer Liver Metastases. 结直肠癌肝转移的右肝切除术前右肝及门静脉栓塞治疗。
IF 0.6 Q4 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2023-01-01 DOI: 10.1159/000529909
Eduardo E Montalvo-Javé, Edwin A Ayala-Moreno, Alejandro Rossano García, Alejandro Díaz Girón Gidi, Jorge Guerrero Ixtlahuac

Colon cancer has had a significant increase in its incidence in recent years. Many of the cases are diagnosed late; it is not unusual that a large number of cases present metastatic disease at the time of diagnosis, and the liver is the main organ where these lesions occur. Surgical approach to this condition has undergone many advances which have allowed a better approach to them. Local techniques such as embolization have gained momentum in recent years and are a great help to the surgical planning. We present the case of a 72-year-old female patient diagnosed with colorectal cancer and metastatic disease. Multiple liver tumors were demonstrated by imaging studies. A staged resection of the primary tumor and the metastatic hepatic tumors was planned. It was decided to perform an embolization of the hepatic artery to cause hypertrophy of the left lobe before the second stage of the surgical approach with good clinical and laboratorial findings after the surgery. Follow-up with adjuvant chemotherapy, imaging studies and tumor markers is planned. Several publications state that surgical approach of metastatic disease is still controversial and that decisions should be made under the context of each patient. Many techniques have shown good results; embolization of the hepatic tumors has a good outcome in the survival rate in selected patients. Hepatic volume and future liver remnant should be always assessed with imaging studies. Each case has to be individualized for the approach of the metastatic disease, always in a coordinated teamwork for maximum benefit of the patient.

近年来,结肠癌的发病率显著上升。许多病例诊断较晚;在诊断时出现大量转移性疾病的病例并不罕见,肝脏是这些病变发生的主要器官。这种情况的手术方法已经取得了许多进展,这使得他们有了更好的方法。栓塞等局部技术近年来发展迅速,对手术计划有很大帮助。我们提出的情况下,72岁的女性患者诊断为结直肠癌和转移性疾病。影像学检查证实多发性肝脏肿瘤。计划对原发肿瘤和转移性肝肿瘤进行分期切除。我们决定在第二阶段手术前对肝动脉进行栓塞以引起左叶肥大,手术后临床和实验室结果良好。计划随访辅助化疗、影像学检查和肿瘤标志物。一些出版物指出,转移性疾病的手术方法仍然存在争议,应该根据每个患者的情况做出决定。许多技术已经显示出良好的效果;肝肿瘤栓塞治疗在特定患者中具有良好的生存率。肝脏体积和未来的肝残余应该通过影像学检查来评估。每个病例都必须针对转移性疾病的方法进行个体化治疗,始终在协调的团队合作中为患者提供最大的利益。
{"title":"Right Hepatic and Portal Vein Embolization before Right Hepatectomy for Colorectal Cancer Liver Metastases.","authors":"Eduardo E Montalvo-Javé,&nbsp;Edwin A Ayala-Moreno,&nbsp;Alejandro Rossano García,&nbsp;Alejandro Díaz Girón Gidi,&nbsp;Jorge Guerrero Ixtlahuac","doi":"10.1159/000529909","DOIUrl":"https://doi.org/10.1159/000529909","url":null,"abstract":"<p><p>Colon cancer has had a significant increase in its incidence in recent years. Many of the cases are diagnosed late; it is not unusual that a large number of cases present metastatic disease at the time of diagnosis, and the liver is the main organ where these lesions occur. Surgical approach to this condition has undergone many advances which have allowed a better approach to them. Local techniques such as embolization have gained momentum in recent years and are a great help to the surgical planning. We present the case of a 72-year-old female patient diagnosed with colorectal cancer and metastatic disease. Multiple liver tumors were demonstrated by imaging studies. A staged resection of the primary tumor and the metastatic hepatic tumors was planned. It was decided to perform an embolization of the hepatic artery to cause hypertrophy of the left lobe before the second stage of the surgical approach with good clinical and laboratorial findings after the surgery. Follow-up with adjuvant chemotherapy, imaging studies and tumor markers is planned. Several publications state that surgical approach of metastatic disease is still controversial and that decisions should be made under the context of each patient. Many techniques have shown good results; embolization of the hepatic tumors has a good outcome in the survival rate in selected patients. Hepatic volume and future liver remnant should be always assessed with imaging studies. Each case has to be individualized for the approach of the metastatic disease, always in a coordinated teamwork for maximum benefit of the patient.</p>","PeriodicalId":9614,"journal":{"name":"Case Reports in Gastroenterology","volume":"17 1","pages":"212-220"},"PeriodicalIF":0.6,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10294023/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9740386","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Rectal Melanoma: Rare Cancer with Grave Prognosis. 直肠黑色素瘤:预后严重的罕见癌症。
IF 0.6 Q4 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2023-01-01 DOI: 10.1159/000529434
Khadija Soufi, Ferheen Abbasi, Dongguang Wei, Rashmi Verma

Malignant melanoma of the rectum is an exceedingly rare type of cancer with an aggressive presentation, comprising up to 4% of all anorectal cancers. Presentation of this cancer tends to occur in individuals in their late 80s, with nonspecific symptoms such as anal pain or rectal bleeding. Diagnosing rectal melanoma, especially in early stages, is difficult due to its amelanotic presentation and lack of pigmentation, which results in poor remission rates and prognosis. Furthermore, surgical treatment is difficult as these types of malignant melanomas tend to spread along submucosal planes; thus, complete resections are impractical, especially if caught later. In this case report, we present the radiological and pathological features as seen in a 76-year-old man diagnosed with rectal melanoma. Based on his presentation of a heterogeneous bulky anorectal mass with extensive local invasion, initial impressions were colorectal carcinoma. However, surgical pathology found the mass to be a c-KIT+ melanoma, with positive SOX10, Melan-A, HMB-45, and CD117 biomarkers. While the patient was treated with imatinib, the melanoma was too widespread and aggressive, leading to progression and ultimately death.

直肠恶性黑色素瘤是一种非常罕见的具有侵袭性表现的癌症,占所有肛肠癌的4%。这种癌症的表现往往发生在80多岁的人身上,有非特异性症状,如肛门疼痛或直肠出血。诊断直肠黑色素瘤,特别是在早期阶段,是困难的,由于其无色素的表现和缺乏色素沉着,这导致缓解率和预后差。此外,手术治疗是困难的,因为这些类型的恶性黑色素瘤往往沿着粘膜下平面扩散;因此,完全切除是不切实际的,特别是如果发现较晚。在这个病例报告中,我们提出了一个76岁男性诊断为直肠黑色素瘤的放射学和病理特征。根据他的表现,他的肛门直肠有一个不均匀的大肿块,并有广泛的局部侵犯,初步印象是结直肠癌。然而,手术病理发现肿块为c-KIT+黑色素瘤,SOX10、Melan-A、HMB-45和CD117生物标志物阳性。虽然患者接受伊马替尼治疗,但黑色素瘤过于广泛和侵袭性,导致进展并最终死亡。
{"title":"Rectal Melanoma: Rare Cancer with Grave Prognosis.","authors":"Khadija Soufi,&nbsp;Ferheen Abbasi,&nbsp;Dongguang Wei,&nbsp;Rashmi Verma","doi":"10.1159/000529434","DOIUrl":"https://doi.org/10.1159/000529434","url":null,"abstract":"<p><p>Malignant melanoma of the rectum is an exceedingly rare type of cancer with an aggressive presentation, comprising up to 4% of all anorectal cancers. Presentation of this cancer tends to occur in individuals in their late 80s, with nonspecific symptoms such as anal pain or rectal bleeding. Diagnosing rectal melanoma, especially in early stages, is difficult due to its amelanotic presentation and lack of pigmentation, which results in poor remission rates and prognosis. Furthermore, surgical treatment is difficult as these types of malignant melanomas tend to spread along submucosal planes; thus, complete resections are impractical, especially if caught later. In this case report, we present the radiological and pathological features as seen in a 76-year-old man diagnosed with rectal melanoma. Based on his presentation of a heterogeneous bulky anorectal mass with extensive local invasion, initial impressions were colorectal carcinoma. However, surgical pathology found the mass to be a c-KIT+ melanoma, with positive SOX10, Melan-A, HMB-45, and CD117 biomarkers. While the patient was treated with imatinib, the melanoma was too widespread and aggressive, leading to progression and ultimately death.</p>","PeriodicalId":9614,"journal":{"name":"Case Reports in Gastroenterology","volume":"17 1","pages":"235-241"},"PeriodicalIF":0.6,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10294269/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9740392","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Traditional Serrated Adenoma of the Ileum with Intussusception Successfully Treated with Laparoscopic Bowel Resection. 腹腔镜下肠切除术成功治疗传统的回肠锯齿状腺瘤伴肠套叠。
IF 0.6 Q4 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2023-01-01 DOI: 10.1159/000529093
Ryo Nishide, Teppei Kamada, Junji Takahashi, Keigo Nakashima, Eisaku Ito, Yuichi Nakaseko, Norihiko Suzuki, Masashi Yoshida, Hironori Ohdaira, Yutaka Suzuki

The most common site of traditional serrated adenomas (TSA) is the area from the left colon to the rectum; however, there are few reports on TSA in the small intestine. Herein, we report a case of TSA of the ileum with intussusception that was diagnosed and successfully treated with laparoscopic bowel resection. The patient was a 29-year-old female with the chief complaint of recurrent abdominal pain and vomiting. Contrast-enhanced computed tomography showed a mass in the ileum and intussusception with the mass as the lead point. The patient was diagnosed with intussusception secondary to a small intestinal tumor. Due to the difficulty in endoscopic treatment resulting from the localization of the lesion, elective laparoscopic surgery was planned. Intra-abdominal examination revealed intussusception of the small intestine in the pelvic ileum, and an elastic soft mass 400 cm from the ligament of Treitz was identified at the lead point of intussusception. Partial laparoscopic resection of the small intestine was performed, with an operation time of 81 min, and a small amount of bleeding. The pathological diagnosis was TSA of the ileum, and the patient's postoperative course was good, with no complications. Seven months after the surgery, no recurrence of symptoms was observed. Therefore, from our case of TSA of the ileum with intussusception that was successfully treated with laparoscopic bowel resection, we conclude that when intussusception of the small intestine occurs, TSA of the ileum with malignant potential is possible, and early diagnosis by resection should be considered.

传统锯齿状腺瘤(TSA)最常见的部位是从左结肠到直肠的区域;然而,很少有关于小肠TSA的报道。在此,我们报告一例回肠TSA合并肠套叠,经腹腔镜肠切除术诊断并成功治疗。患者为29岁女性,主诉为反复腹痛和呕吐。增强计算机断层扫描显示回肠和肠套叠有肿块,肿块为导点。患者被诊断为继发于小肠肿瘤的肠套叠。由于病变定位,内镜治疗困难,计划择期腹腔镜手术。腹内检查显示盆腔回肠小肠肠套叠,肠套叠起始点距Treitz韧带400 cm处发现一弹性软块。行腹腔镜小肠部分切除术,手术时间81 min,少量出血。病理诊断为回肠TSA,患者术后病程良好,无并发症。术后7个月无症状复发。因此,从我们的回肠TSA合并肠套叠经腹腔镜肠切除术成功治疗的病例来看,我们认为当小肠发生肠套叠时,回肠TSA有恶性的可能,应考虑早期切除诊断。
{"title":"Traditional Serrated Adenoma of the Ileum with Intussusception Successfully Treated with Laparoscopic Bowel Resection.","authors":"Ryo Nishide,&nbsp;Teppei Kamada,&nbsp;Junji Takahashi,&nbsp;Keigo Nakashima,&nbsp;Eisaku Ito,&nbsp;Yuichi Nakaseko,&nbsp;Norihiko Suzuki,&nbsp;Masashi Yoshida,&nbsp;Hironori Ohdaira,&nbsp;Yutaka Suzuki","doi":"10.1159/000529093","DOIUrl":"https://doi.org/10.1159/000529093","url":null,"abstract":"<p><p>The most common site of traditional serrated adenomas (TSA) is the area from the left colon to the rectum; however, there are few reports on TSA in the small intestine. Herein, we report a case of TSA of the ileum with intussusception that was diagnosed and successfully treated with laparoscopic bowel resection. The patient was a 29-year-old female with the chief complaint of recurrent abdominal pain and vomiting. Contrast-enhanced computed tomography showed a mass in the ileum and intussusception with the mass as the lead point. The patient was diagnosed with intussusception secondary to a small intestinal tumor. Due to the difficulty in endoscopic treatment resulting from the localization of the lesion, elective laparoscopic surgery was planned. Intra-abdominal examination revealed intussusception of the small intestine in the pelvic ileum, and an elastic soft mass 400 cm from the ligament of Treitz was identified at the lead point of intussusception. Partial laparoscopic resection of the small intestine was performed, with an operation time of 81 min, and a small amount of bleeding. The pathological diagnosis was TSA of the ileum, and the patient's postoperative course was good, with no complications. Seven months after the surgery, no recurrence of symptoms was observed. Therefore, from our case of TSA of the ileum with intussusception that was successfully treated with laparoscopic bowel resection, we conclude that when intussusception of the small intestine occurs, TSA of the ileum with malignant potential is possible, and early diagnosis by resection should be considered.</p>","PeriodicalId":9614,"journal":{"name":"Case Reports in Gastroenterology","volume":"17 1","pages":"76-81"},"PeriodicalIF":0.6,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/30/b2/crg-2022-0017-0001-529093.PMC9906037.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10745662","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Case Reports in Gastroenterology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1